Obesity

Pharma company acquires patent rights to Peptide YY for obesity

Published in Obesity and Diabetes Week, December 20th, 2004

Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced that it has acquired exclusive worldwide rights to patents and patent applications from the University of Cincinnati covering analogs of Peptide YY, or peptide derivatives, in the fields of obesity, appetite suppression, reducing food intake, inducing weight loss and inducing satiety.

The agreement includes exclusive commercial rights to issued U.S. patent 5,604,203, which relates to analogs of Peptide YY, or peptide derivatives, and uses thereof as therapeutic agents in the treatment of gastroenterological disorders; issued U.S. patents 6,013,633, 6,235,718 and 6,737,408, which relates to compounds for control...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-12-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry